Full Press Release Details
and Senesco Announce Wood Quality Results
S.C., July 7 /PRNewswire/ -- ArborGen, LLC, a leader in forest tree
improvement technologies, today announced wood quality results from ongoing
field trials that are utilizing technology in-licensed from Senesco
Technologies, Inc. (NYSE AMEX: SNT). The two companies had previously
announced that trees that incorporate Senesco technology have shown
significantly enhanced growth rates in 3-year-old field trials.
trees from the field trials were harvested and their wood chemistry and density
was assessed. There were no differences in key economic characteristics of wood,
such as lignin, cellulose, and specific gravity, between the trees with the
enhanced growth attributes and untreated control trees. This is good
news as fast tree growth is often associated with lower wood
several years of positive field trials, Senesco's technology has certainly given
us confidence in the consistency of performance of this technology," said
Barbara Wells, Ph.D., president and CEO of ArborGen. "Our collaboration with
Senesco continues to produce very promising results that we expect will
ultimately add to our portfolio of forestry products."
Galton, President and CEO of Senesco, said, "We believe ArborGen's results
represent another step toward the commercial validation of our technology in the
hands of our licensing partners. Partnering with companies with ArborGen's
expertise allows for development of our technology for agricultural
applications, while our internal research and development remains focused on our
near term goal of filing an Investigational New Drug application with the FDA
for our ongoing oncology work in multiple myeloma. We believe these
results further reaffirm the broad applicability of Senesco's
is a leader in tree improvement and the commercial production of trees. We are
dedicated to helping the global forest industry meet the growing demand for
wood, pulp & paper, and energy in a more productive and sustainable way.
Enabling more wood to be grown on less land helps conserve the world's native
forests in all their beauty, diversity and complexity. With one of the world's
most extensive tree germplasm resources, ArborGen uses both traditional breeding
and advanced genetic technologies, to discover and produce high yield seedlings
for our customers, allowing our customers to significantly increase the
productivity of their forests and manufacturing processes. Our mission is to
deliver superior performing trees through innovative science and world class
customer service -- every tree, every time. For more information, please visit
Senesco Technologies, Inc.
Technologies, Inc. is a U.S. biotechnology company, headquartered in New
Brunswick, NJ. Senesco has initiated preclinical research to trigger
or delay cell death in mammals (apoptosis) to determine if the technology is
applicable in human medicine. Accelerating apoptosis may have applications
to development of cancer treatments. Delaying apoptosis may have
applications to certain inflammatory and ischemic diseases. Senesco takes
its name from the scientific term for the aging of plant cells:
senescence. Delaying cell breakdown in plants extends freshness after
harvesting, while increasing crop yields, plant size and resistance to
environmental stress. The Company believes that its technology can be used
to develop superior strains of crops without any modification other than
delaying natural plant senescence. Senesco has partnered with leading-edge
companies engaged in agricultural biotechnology and earns research and
development fees for applying its gene-regulating platform technology to enhance
its partners' products.
statements included in this press release are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Actual results could differ materially from such statements
expressed or implied herein as a result of a variety of factors, including, but
not limited to: the ability of Senesco to consummate a financing; the
development of Senesco's gene technology; the approval of Senesco's patent
applications; the successful implementation of Senesco's research and
development programs and joint ventures; the success of Senesco's license
agreements; the acceptance by the market of Senesco's products; success of
Senesco's preliminary studies and preclinical research; competition and the
timing of projects and trends in future operating performance, Senesco's ability
to meet its funding milestones under its financing transaction, Senesco's
ability to continue to comply with the continued listing standards of the AMEX,
as well as other factors expressed from time to time in Senesco's periodic
filings with the Securities and Exchange Commission (the "SEC"). As a
result, this press release should be read in conjunction with Senesco's periodic
filings with the SEC. The forward-looking statements contained herein
are made only as of the date of this press release, and Senesco undertakes no
obligation to publicly update such forward-looking statements to reflect
subsequent events or circumstances.
of Communication & Public Affairs
Investors, Brian Ritchie of FD, for Senesco, +1-212-850-5600, brian.ritchie@fd.com;
or Nancy M. Hood, Director of Communication & Public Affairs of ArborGen,
+1-843-851-5077, Cell, +1-843-323-1509, nmhood@arborgen.com